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SHnlmlry 
It has been suggested that sdf major histocompatibility complex (MHC) peptides bound to self 
MHC molecules may be involved in the intrathymic induction of self tolerance. We studied the 
antigenicity of synthetic peptides derived from the first domain of  DRBI*0101 chain in a DRBI*0101 
responder. We found that a peptide corresponding to residues 21-42 of the/3 chain could elicit 
the proliferation of autoreactive T cells. A T cell line (TCL-SUN) and 7 of 9 T ceil clones (TCC) 
derived from TCL-SUN specifically recognized peptide 21-42 in the presence of APCs carrying 
the DRBI*0101 allele. DRBI*0101 positive APCs stimulated the TCCs in the absence of peptide, 
although the magnitude of the response was much lower than in cultures with peptide.  This 
suggests  that self DR1 molecules are continuously processed into peptides  that are presented 
by the DR1 molecules on the surface of the cells. The data indicate that some T calls whose 
TCR binds to self MHC peptides presented by self MHC molecules are not deleted, although 
their ligand is continuously present.  TCCs specific for peptide 21-42 presented in the context 
of DR1 were also stimulated by calls heterozygous for DRBI*0301 and 1601, indicating that 
some DR peptide-specific autoreactive T  ceils participate  in alloreactivity. 
I 
t is now widely accepted that recognition of self MHC 
molecules by T cells during and after T ceil development 
is the driving force that shapes the available repertoire (1-5). 
Positive sdection may operate on the basis of low affinity 
TCR-MHC interactions, whereas negative selection may dim- 
inate only high affinity interactions (1). MHC molecules act 
as peptide binding molecules for presentation  of foreign an- 
tigen to helper and cytotoxic T ceUs (6, 7). Most self pro- 
teins are processed and presented as peptides in the context 
of selfMHC molecules (8). Such complexes have been impli- 
cated in both positive and negative selection in the thymus 
(2-5). 
Recent evidence indicates that both class I and class II self 
MHC  molecules  are processed  into peptides  that  can be 
presented in the context of other self class II molecules at 
the surface of APCs (9-13). Using a mAb that detects a com- 
plex formed by I-A  b with peptide Eoe 56-73 of I-E  b, Ruden- 
sky et al. (12) have shown that the complexes of self MHC 
molecule and self peptide derived from another self MHC 
molecule are expressed on APCs in thymic medulla, mediating 
negative sdection, e.g., deletion of the T cells recognizing 
the complex.  However,  there is  also evidence  that  some 
self MHC peptide-reactive T cells escape elimination resulting 
in incomplete peripheral tolerance (14). In the mouse, both 
dass I and II MHC peptides were shown to interact efficiently 
with class II molecules to induce an autoreactive T cell prolifer- 
ative response (14). Such autoimmunogenic peptides appear 
to represent cryptic epitopes, i.e., determinants that are not 
optimally processed and presented by APCs. 
We have attempted to establish whether peptides derived 
from the amino acid sequence of the/Jl chain of HLA-DR 
can induce T cell autoreactivity.  In this paper, we describe 
a T cell line and clones generated by in vitro immunization 
of peripheral blood mononudear ceils from a healthy donor, 
carrying the DRBI*0101/DR~I*1403 genotype, with a pep- 
tide corresponding to residues 21-42 of the DRBI*0101 chain. 
This DR1 peptide is presented by the DR1 molecule, being 
recognized by  T  cells  only  on  APCs  that  express the 
DRBI*0101 gene. Autoreactive peptide-specific T ceils also 
respond to the native DRBI*0101 molecule on the surface 
of APCs, suggesting that the naturally processed form of pep- 
tide 21-42  is continuously presented  by self DRgl*0101 
molecule. 
Materials and Methods 
Peptide Synthesis.  Synthetic  peptides corresponding  to residues 
1-20 (peptide 1), 21-42 (peptide 2), 43-62 (peptide 3), and 66-90 
(peptide 4) of the DRBI*0101 chain (15) were synthesized  by the 
general solid-phase  methods described  by Merrifield  et al. (16) using 
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City, CA). Peptides  were purified  by reverse-phase  chromatography. 
Each peptide chromatographed as a single peak, showed the ex- 
pected amino acid composition, and >95% purity. Peptides were 
dissolved at a concentration of 1 mg/ml in KPMI 1640 medium, 
and further  diluted to appropriate concentrations with culture 
medium. 
Generation ofPeptide-specific T CelI Line and Clones.  Responding 
calls were PBMC from a healthy male donor (SUN) whose HLA- 
DRBI*  genotype is DRBl*0101/1403. PBMC at  l@/ml were 
stimulated in 24-well plates (Costar, Cambridge, MA) with 10 
~g/ml of peptide 2 in P,  PMI 1640 medium supplemented with 
10% human serum (Sigma Chemical Co., St. Louis, MO), 2 mM 
t-glutamine, and 50 ~g/ml gentamicin (Gibco, Grand Island, NY). 
rlL-2 was added at 10 U/ml 3 d after initiation of the culture. The 
cultures were subsequently  fed every  3-4 d with medium containing 
20 U/ml ri1r  and restimulated every 14 d with peptide 2, using 
as APCs irradiated (3,000 rad) autologous PBMCs at 2  x  106/ml 
(10). A line that responded to peptide 21-42 was obtained after 
two stimulations, and was cloned by limiting  dilution  at  0.5 
cells/well in medium containing this peptide (10/~g/ml), rlL-2 (20 
U/ml),  and  autologous  irradiated  PBMC  (5  x  104/well). 
Growing clones were expanded and restimulated under the same 
conditions as described for the line. 
Proliferation Assays.  Responding T cells (2  x  104/well) were 
stimulated with peptides (2.5 ~tg/ml) in the presence of 5  x  104 
irradiated APCs  in  96-well round  bottomed  microtiter  plates 
(Costar). In some experiments, responding T cells  were challenged 
only with irradiated PBMCs. After 48 h, the cultures were labeled 
with tritiated thymidine (0.5/~Ci/well) and harvested 18 h later. 
[3H]TdR incorporation was then measured in a liquid scintillation 
counter (LKB Betaplate; Pharmacia LKB Nuclear, Gaithersburg, 
MD). Mean cpm of triplicate cultures and the SD of the mean 
were calculated. 
Antibody Blocking Assay.  Blocking  assays  were performed using 
supernatants from mAbs L243 and W6/32 (American Tissue Cul- 
ture Collection, R_ockville,  MD) which recognize framework de- 
terminants of HLA-DR and of HLA-class I antigens, respectively. 
Anti-DP, DO~ CD4, and CD8 antibodies (Becton Dickinson & 
Co., Mountain View, CA) were dialysed  against medium and used 
at 1/~g/ml. mAb TM-903, generated  in our laboratory,  reacts with 
HLA-DR,81*0301 and is negative  with HLA-Dl~l*1601 (17). All 
mAbs tested were added to the cultures at the initiation of the 
proliferative assay. 
HLA-typing.  The HLA-DR~I*  genotypes of cell used in the 
assays were determined by genomic typing of in vitro amplified 
DNA with sequence-specific oligonudeotide probes (SSOP) for 
DRBI* alleles, using PCK primers, and SSOP provided by the XI 
International Histocompatibility Workshop, Yokohama, Japan. 
PCR Analysis of V~ Gene Usage.  Total  KNA preparation was 
performed as described by Auffray and Rougeon (18) with some 
modifications as previously described (13). The KNA was reverse 
transcribed into cDNA with Moloney Murine Leukemia  Virus re- 
verse transcriptase (13). The conditions used for PCK and the se- 
quences of V~ and C~ primers were described  by Choi et al. (19). 
Briefly, 2/xl cDNA from individual samples were amplified  in the 
presence of 0.3 #M of a V/3 specific primer and a 3' CB primer, 
2.5 U ofTaq polymerase (Perkin Elmer Corp., Norwalk, CT), 200 
#M dNTPs and PCK buffer containing 1.5 mM MgCI2, 50 mM 
KC1, and 10 mM Tris-HC1 (pH 8.4). The amplification was per- 
formed in a thermocyder (Perkin-Elmer Cetus Corp.) for 25 cycles: 
95~  melting, 55~  annealing,  and 72~  extension  for I min each. 
The amplified products were separated on 2% agarose gel. 1 #g 
Table  1.  Response of TCL-SUN  to DR1  Peptides 
DR1 peptide  [3H]TdR Incorporation 
APC  residues  (TCL-SUN) 
+  Medium  8,796 
-  21-42  239 
+  1-20  9,321 
+  21-42  40,372 
+  43-62  9,082 
+  66-90  9,268 
TCL-SUN was tested  for reactivity  to peptide  21-42 (2.5/~g/ml)  in tripli- 
cate cultures using 2 x 104 responding  cells and 5 x 104 irradiated  au- 
tologous APCs/well.  Cultures  were labeled  after  48 h and harvested 18 h 
later. Results are expressed as mean cpm. SD is <10%. 
of HaelII-digested r  x  174 DNA (Gibco, BILL) was run in par- 
allel as molecular weight markers. 
Results 
Generation  of TCLI-SUN.  In previous studies we have 
shown  that  T  cells  from both  DtL81*0101  positive  and 
negative individuals respond to synthetic 20-mer peptides de- 
rived from the amino acid sequence  of the first domain of 
the DRBI*0101 chain (13). Peptide 2 (residues  21-42)  was 
used in the present  studies for in vitro immunization of 
PBMC from individual SUN carrying the DR/31"0101  and 
DRf11*1403 alleles. TCL-SUN was obtained after two cycles 
of stimulation. The line was tested for reactivity to peptide 
2, and to peptides 1, 3, and 4, used as controls, in the pres- 
ence of autologous APCs (Table 1). TCbSUN exhibited strong 
blastogenic responses  to peptide 2. The line also responded 
to autologous APCs without added peptide, although this 
reaction was about fourfold weaker than that observed when 
peptide 2 was added. The response to peptides 1, 3, and 4, 
was of the same order of magnitude as that observed in cul- 
tures with APCs alone, suggesting that reactivity to the specific 
immunogen does not reflect the response to impurities con- 
tained in the peptide preparation. Thus, TCL-SUN responds 
specifically to peptide 2 presented by autologous APCs. 
To identify the MHC-restrictive element required for rec- 
ognition of peptide 2, TCL-SUN was tested for reactivity 
to this peptide in the presence of APCs sharing one or none 
of the DR alleles with the responder (Table 2). APCs from 
unrelated donors carrying the DRBI*0101 allele were capable 
of presenting peptide 2 to TCL-SUN, and of eliciting au- 
toreactivity, with the same efficiency as autologous APCs. 
PBMCs expressing DI~1"0102 could neither present the pep- 
tide nor serve as targets, although DP-~1"0102 differs from 
DILBI*0101 by only two amino acid residues in the first do- 
main of the B1 chain. APCs sharing the DRB1*1403 gene 
1 Abbreviations used in this paper: TCC, T cell clone; TCL, T cell line. 
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[~H]TdR Incorporation 
(TCL-SUN) 
APC  No  Pe'ptide 
Cell  DRB1 * Genotype of APC  alone  peptide  21-42 
No APC  354  310 
1  DRB1*0101/1403  124  8,796  37,366 
2  DRB1*0101/0301  193  9,079  38,669 
3  DRB1*0102/0901  133  264  225 
4  DRB1*1403/0901  284  257  268 
5  DRB1*0301/1601  203  19,573  20,250 
6  DRB1*0301/1601  110  13,600  15,144 
7  DRB1*0301/1101  54  64  75 
8  DR~1"1601/1301  38  1,301  1,425 
9  DR~1"1601/1201  153  391  362 
10  DI~1"1601/1101  165  300  234 
11  DRBl*1601/07  133  266  280 
TCL-SUN was tested for reactivity to peptide 21--42 (2.5 #g/ml) in the presence  of APCs carrying different DR alleles.  The reactions were set 
up as described in Table 1. 
with the responder elicited no stimulation in cultures with 
or without peptide 2. This indicates that the DRIll*0101 
molecule serves as a restrictive element and that it elicits au- 
toreactivity. 
TCL-SUN also reacted to APCs from two donors (cells 
5 and 6) expressing the DRBl*0301/1601  genotype in cul- 
tures without added peptide. These DR3/DR16 heterozy- 
gous APCs, however, were unable to present peptide 2, since 
no additional stimulation was observed when peptide 2 was 
added to the cultures.  APCs expressing only one of these 
genes, i.e., either DRBI*0301 or 1601, however,  did not stimu- 
late the response with or without added peptide. Hence, the 
stimulatory moiety recognized by TCL-SUN on the surface 
of DRBl*0301/1601  heterozygous cells may be a structure 
that resembles the complex formed by peptide  2 with the 
DRBI*0101  molecule. 
Characterization of TCCs Derived.from TCLSUN.  Rec- 
ognition of peptide 2 in the context of DR1 molecule, and 
recognition of DR1 positive APCs without exogenous pep- 
tide, may be carried out by two different sets of T cells com- 
prised in TCI~SUN.  For this reason, we cloned the line by 
limiting dilution, and characterized  nine of the resulting clones 
(Table 3). Seven clones responded both to DRBI*0101 posi- 
tive APCs without added peptide, and to peptide 2 presented 
by these APCs, in a pattern identical to that of the line. All 
seven clones displayed strong blastogenic  responses when 
stimulated  with  DRBl*0301/1601  heterozygous  APCs. 
Similar to TCL-SUN, these clones did not react against cells 
expressing only DtL81*0301 or DR~1"1601.  This indicates 
that they recognize a structure presented by the heterozy- 
gnus cells, and that this ligand resembles the complex formed 
by peptide 2 with the DRBI*0101  molecule. 
The observation that these clones recognize DRBI*0101 
APCs without the addition of exogenous peptide  suggests 
that peptide 2 emerges from the natural processing of the 
DR1 molecule and that it binds to the DR1 molecule per 
se. Since the blastogenic response to autologous APCs is about 
eightfold weaker in the absence than in the presence of pep- 
tide 2, it appears that the amount of naturally processed self- 
peptide that binds to MHC does not saturate all the antigen 
binding sites on the DR1 molecule. 
Two other dones, E1B2 and E2B2, reacted strongly against 
DRBI*0101  positive APC. These TCCs,  however, showed 
no enhanced blastogenesis when peptide 2 was added. TCC 
E1B2 and E2B2 also failed to recognize the DRBl*0301/1601 
heterozygous APCs, supporting the concept that these APCs 
express a structure which resembles the peptide 2/DR1 mol- 
ecule complex. 
These results, therefore, indicate that TCbSUN comprises 
two populations  of T cells: one which recognizes the syn- 
thetic or the naturally processed form of peptide  21-42 in 
context of  DR1; the other which recognizes the DR1 mole- 
cule, probably together with an unknown peptide. It is pos- 
sible that the higher level of autoreactivity displayed by TCb 
SUN to APCs alone compared with the clones, reflects the 
summation of autoreactivity to self DR1 plus unknown pep- 
tide, and self DR1 plus (naturally processed) DR1 peptide 
21-42. 
mAbs Blocking Studies.  Study of the reactivity to peptide 
2 displayed by TCbSUN and by TCC derived from it, have 
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DRBI* Genotype of APCs 
Peptidr  0101/  0101/  0301/  1403/  0301/  1601/ 
TCCs  21-42  1403  0301  1601  0901  1101  1301 
FB2  -  5,964  7,011  26,094  514  318  451 
+  45,570  48,303  27,358  470  241  445 
FB3  -  3,615  3,871  11,556  270  219  208 
+  27,688  25,448  11,911  316  148  140 
FB4  -  3,449  3,820  23,735  395  564  463 
+  28,891  31,202  23,166  544  401  363 
FC2  -  3,639  3,442  20,506  200  234  369 
+  21,564  18,998  19,857  263  109  413 
FC4  -  6,518  6,350  26,353  444  580  503 
+  49,972  49,020  31,387  596  526  811 
FC  5  -  5,688  5,193  24,064  457  494  647 
+  43,627  45,106  27,322  518  479  432 
EIC2  -  3,322  3,318  16,895  322  333  323 
+  25,939  25,052  18,755  469  550  337 
EIB2  -  13,392  13,151  375  412  290  250 
+  13,218  13,926  368  285  363  366 
E2B2  -  13,629  16,491  468  302  118  722 
+  16,463  18,880  480  675  248  360 
TCCs were tested for reactivity to peptide 21-42 (2.5/xg/ml).  The reactions were set up as described in Table 1. 
revealed that the peptide is presented on the DILl molecule. 
To confirm the observation that the response is HLA-DR 
restricted, we tested the reactivity of TCL-SUN and of one 
of the clones (FC4) to the peptide and to autologous APCs 
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Figm~ 1.  Effect  of mAbs on proliferative  responses of TCDSUN and 
TCC-r-.C4. Autologo~ APCs (5  x  l~/wdl) were cultured with 'rcL- 
SUN (A) and TCC-FC4 (B) (2  x  10Vwell)  in the presence (N) or in 
the absence (m) of peptide 21-42 (2.5/~g/ml). mAbs were added at the 
initiation of the cultures. Results are mean ~m of triplicate  cultures. SD 
to the mean is <10%. 
in the presence of mAb anti-HLA-dass I and class II, and 
anti-CD4  and  CD8.  mAb  to  HLA-DR  and  to  CD4 
significantly inhibited the TCL and TCC response induced 
by autologous APCs with and without peptide,  mAbs to 
HLA-DQ, DP, class I, and CD8 had no effect (Fig. 1). 
In an attempt to establish whether the ligand recognized. 
by TCbSUN on the DtL81*0301/1601 heterozygous cells 
consists of a DR3 molectde plus peptide, or DR16 molecule- 
plus-peptide complex, we used mAb TM-903 which reacts 
3O 
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Figure 2.  Effect of mAbs on the proliferative  response of TCI,  SUN 
to DR16/DR3 heterozygous cells. TCbSUN (2  x  104/well)  was stimu- 
lated wi~ DR16/DR.3 heterozygous cells (5  x  104/well)  in the presence 
of mAbs. Results are expressed as mean  cpm. SD to the mean is <10%. 
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EIB2. RNAs from TCIzSUN (A), TCC-FC4 (B), and 'ICC-E1B2 (C) 
were reverse  transcribed, PCK amplified  and electrophoresecl  on 2% agarose 
gel. 1 #g HaeIII-digested c# x  174 DNA was run in paralld as molecular 
weight markers. 
with DRBI*0301, but not with DRBl*1601 positive cells 
in blocking experiments (17). The response was inhibited by 
mAb to a common structure determinant of HLA-DR, but 
not by the anti-DR3 mAb TM-903 (Fig. 2). This suggests 
that reactivity is triggered by a DR16-plus-peptide rather than 
DR3-plus-peptide complex. Since both the DR16 and DR3 
antigens, however,  are required for stimulation to occur,  it 
is possible that the peptide itself derives from DR3, or from 
the product of a linked gene. 
V~ Gene Expression in TCLSUN and TCCs.  To estab- 
lish the donality of the cells that recognize peptide 21-42 
we studied the TCR-V~3 gene usage in TCI.-SUN and in each 
of the nine clones derived from it. Complete analysis of the 
expression of mRNA for 20 families of human TCR-Vfl genes 
showed three bands corresponding to VBT, V~19, and VB20 
in TCI,  SUN (Fig. 3 A). The strongest message corresponded 
to VB7. All seven clones that recognize peptide 2 in context 
of DRBI*0101 showed a single band corresponding to Vfl7 
as illustrated in Fig. 3 B. The two clones with reactivity against 
autologous APCs, but not against the peptide, expressed Vf119 
(Fig.  3 C).  Therefore, the response to self HLA-DR1 and 
to sdf-HLA-DRl-plus-peptide 21-42 is the function of dis- 
tinct TCKs. 
Discussion 
The T cell repertoire is shaped by both positive and nega- 
tive selection (1-5). Self peptides are not expected to be im- 
munogenic because of the deletion of T cells recognizing self 
peptide/MHC complexes during intrathymic development. 
It has recently been shown that a self I-E  b peptide can be 
eluted from self I-A  b molecules (20), and that the I-E  b pep- 
tide  is  immunogenic for  I-A  b+,  I-E-  mice,  but  not  for 
I-A  b+, FE  b+ mice (12). These results suggest that T cell rec- 
ognition of self MHC peptides expressed on the cell surface 
in association with selfMHC molecules leads to the elimina- 
tion of T  cells recognizing such complexes.  On the other 
hand, the existence of autoreactive T cells that recognize self 
MHC  peptide/MHC  molecule complexes has  also  been 
documented, although it was not proven that such comploms 
were naturally expressed on APCs (14). 
The data presented in this paper demonstrate that autoreac- 
tire human T  cells, which are specific for a self DR1 pep- 
tide/stir DR1 molecule complex, escape negative selection, 
in spite of the fact that the complexes are expressed on pe- 
ripheral APCs. We studied the antigenicity of a peptide cor- 
responding to residue 21-42 of the DP,431"0101 chain using 
this peptide for in vitro immunization of T  cells from an 
individual carrying this allele. T cell lines and clones specific 
for the DR1 peptide 21-42 presented by DRBI*0101 posi- 
tive APCs were obtained. These lines were stimulated, al- 
though to a lesser degree, by DtL81*0101 positive APCs even 
in the absence of the peptide. This suggests that self DR1 
molecules are continuously processed and presented on the 
surface of APCS, raising questions about mechanisms sup- 
pressing and/or preventing the activation of anti-sdf MHC- 
reactive  T  cells. 
Rudensky et al. (12) have suggested that differential  ex- 
pression of self peptide/MHC molecule complexes on thymic 
APCs may be a key feature for positive and negative selec- 
tion. In this context, it is possible that autoreactive T cells, 
such as those described in our studies, have escaped tolerance 
induction because the DR1 peptide./DR1 molecttle complexes 
which they recognize, are not expressed on the thymic APCs 
involved in negative selection. This mechanism, howev~, does 
not explain why such potentially autoreactive T cells are not 
activated in the periphery where the DR1 peptide is presented 
by APCs. Since DR1 positive APCs become more stimula- 
tory when exogenous DR1 peptide is added, it is possible 
that the level of expression of DR1 peptide/DR1 molecule 
complexes in the thymus is too low for tolerance induction. 
For the same reason, DR1 peptide-specific T cells in the pe- 
riphery may not be activated  under normal conditions. 
On the other hand, Benichou et al. (14) have demonstrated 
that some sdf MHC peptides interact efficiently with self 
MHC-class II molecules, eliciting autoreactive T cell prolifer- 
ative responses,  while others can bind but fail to stimulate 
reactivity. These authors suggest that there is a hierarchy of 
dominance among T cell determinants resulting from the pro- 
cessing of complex proteins (21, 22). T ceils recognizing dom- 
inant determinants of self  proteins, including self MHC mol- 
ecules,  are likely to be made tolerant  during intrathymic 
development, while T cells specific for cryptic determinants 
could escape negative selection (14). Peptide 21--42 of DR1 
may represent such a cryptic or subdominant determinant 
of the  DR1  molecule which  is  probably  not  optimally 
processed  and presented. 
It has also been suggested that self peptide/MI-IC com- 
plexes at levels sufficient to activate  naive CD4 T  cells are 
of very limited complexity (12). By analogy, peptide 21-42 
may be a dominant determinant of the DR1 molecule which 
fails to compete efficiently for binding to sdfDK1 molecules 
with dominant determinants of other self proteins. This pos- 
sibility, as well as the hypothesis that peptide 21-42 corre- 
sponds to a cryptic epitope, implies that this sdf DR1 pep- 
tide/DR1 molecule complex occurs at a levd that is suboptimal 
1667  Liu et al. for tolerance induction in the thymus, and for T cell activa- 
tion in the periphery. 
It is possible that the failure to eliminate all self-reactive 
T cells prevents excessive purging of the T cell repertoire by 
the immune system (14).  Some self MHC peptide-reactive 
T  cells  may  have  a  physiologic  role  recognizing  certain 
pathogens by molecular mimicry. Such a mechanism may also 
account for alloreactivity, since complexes of aUogeneic MHC 
plus peptide can mimic those formed by self MHC with pep- 
tide (23). Our finding that DR1 peptide-specific autoreac- 
tive T  cells also  recognized allogeneic MHC-plus-peptide 
complexes (presumably presented by the DRBl*0301/1601 
heterozygous cells) supports this notion. 
The existence of potentially autoreactive T cells in the pe- 
riphery as documented in our study, supports the hypothesis 
that such cells can be involved in autoimmune reactions under 
conditions of upregulation of MHC expression. Since the 
TCR-VB gene usage of autoreactive T ceils is quite limited, 
the potential usefulness of antiidiotypic therapy for down- 
regulation of autoaggressive clones can be envisioned. 
The authors acknowledge the secretarial assistance of L. Acosta. 
This work was supported in part by National Institutes of Health grant RO1-A125210-04. 
Address correspondence to Dr. Nicole Suciu-Foca, College of Physicians  & Surgeons of Columbia Univer- 
sity, 630 West 168th Street, P & S 14-403, New York, NY  10032. 
Received for tmblication  4  December  I991. 
References 
1.  Robe),, E., and J. Urbain. 1991, Tolerance and immune regu- 
lation. Immunol.  Today. 12:175. 
2.  Nikolic-Zugic,  J., and M.J. Bevan. 1990. Role of sdf-peptides 
in positively selecting the T-cell repertoire. Nature (Lond.). 
344:65. 
3.  Berg, L.J., G.D. Frank, and M.M. Davis. 1990. The effects 
of. MHC gene dosage and allelic variation on T cell receptor 
selection. Cell. 60:1043. 
4.  Arnold,  B., M.  Messerle, L. Jatsch,  G. Kublbeck, and U. 
Koszinowski. 1990. Transgenic mice expressing a soluble for- 
eign H-2 class I antigen are tolerant to allogeneic fragments 
presented by self  class I but not to the whole membrane-bound 
alloantigen. Proc. Natl. Acad. Sci. USA.  87:1762. 
5.  Murphy, K.M., A.B. Heimberger, and D.Y. Loh. 1990. Induc- 
tion by antigen  of intrathymic  apoptosis of CD4+CD8 + 
TCR  1~ thymocytes in vivo. Science (Wash. DC).  250:1720. 
6.  Babbitt, B.P., P.M. Alien, G. Matsueda, E. Haber, and E.K. 
Unanue. 1985. Binding of immunogenic peptides to Ia histo- 
compatibility molecules. Nature (Lond.). 317:359. 
7.  Townsend, A.R.M., J. Rothbard,  F.M. Gotch, G. Bahadur, 
D. Wraith, and A.J. McMichael.  1986. The epitopes  of  influenza 
nucleoprotein recognized by cytotoxic T lymphocytes can be 
defined with short synthetic peptides. Cell. 44:959. 
8.  Kourilsky, P., G. Chaouat, C. Rabourdin-Combe, and J.-M. 
Claverie. 1987. Working principles in the immune system  im- 
plied by the "peptidic self  ~' model. Proc. Natl. Acad. Sci. USA. 
84:3400. 
9.  DeKoster, H.S., D.C. Anderson, and A. Termijtelen. 1989. T 
cells sensitized to synthetic HLA-DR3 peptide give evidence 
of continuous presentation of denatured HLA-DR3 molecules 
by HLA-DP. J. Exlx Med.  169:1191. 
10.  Chen, B.P., A. Madrigal, and P. Parham. 1990. Cytotoxic T 
cell recognition of an endogenous  class I HLA peptide presented 
by a class II HLA molecule. J. Exp.  Med.  172:779. 
11.  Murphy, D.B., D. Lo, S. Ruth, R.L. Brinster, R.A. Flavell, 
A, Slanetz, and C.A. Janeway,  Jr. 1989. A novel MHC class 
II epitope expressed in thymic medulla but not cortex. Nature 
(Lond.). 338:765. 
12.  Rudensky, A.Y., S. Ruth, P. Preston-Hurlburt, D.B. Murphy, 
and C.A. Janeway,  Jr. 1991. On the complexity of sdf. Nature 
(Lond.). 353:660. 
13.  Liu, Z., N.S. Braunstein, and N. Suciu-Foca. 1992. T cell rec- 
ognition of allopeptides in context of syngeneic MHC. J. Im- 
munol.  148:35. 
14.  Benichou, G., P.A. Takizawa, P.T. Ho, C.C. Killion, C.A. 
Olson, M. McMillan,  and E.E. Sarcarz. 1990. Immunogenicity 
and tolerogenicity  of self-major  histocompatibility  complex  pep- 
tides. J. Ext~ Med.  172:1341. 
15.  Bell, J.I., D. Denney, L. Foster, T. Belt, J.A. Todo, and H.O. 
McDevitt. 1987. Allelic variation in the DR subregion of the 
human major histocompatibility  complex. Proc. Natl. Acad. Sci. 
USA.  84:6234. 
16.  Marglin, A., and R.B. Merrifield. 1970. Chemical synthesis 
of peptides and proteins. Annu.  Rev. Biochem. 39:841. 
17. Liu, Z., S. Tugnlea, E. Reed, and N. Suciu-Foca. 1991. Gener- 
ation of Murine mAbs to HLA-Class I and Class II Antigens. 
In HLA 1991. Vol. 1. Tsuji et al., editors. Oxford University 
Press, Tokyo. In press. 
18.  Auffray,  C., and F. Rougeon. 1980. Purification of mouse im- 
munoglobulin heavy-chain  messenger RNAs from total my- 
eloma tumor RNA.  Eur. J. Biochem.  107:303. 
19.  Choi, G., B. Kotzin, L. Herron, J. Callahan, P. Marrack, and 
J. Kappler. 1989. Interaction of Staphylococcus aureus toxin "su- 
perantigens" with human T cells. Proc. Natl. Acad. Sci. USA. 
86:8941. 
20.  Rudensky, A.Y., P. Preston-Hurlburt, S.-C. Hong, A. Barlow, 
and C.A. Janeway,  Jr. 1991. Sequence  analysis  of  peptides  bound 
to MHC dass II molecules. Nature (Lond.). 353:622. 
21.  Gammon, G., and E. Sercarz. 1989. How some  T cells escape 
tolerance induction.  1989. Nature (Lond.). 342:183. 
22.  Schild, H., O. Rotzschke, H. Kalbacher, and. H.-G.  Ram- 
mensee. 1990. Limit ofT cell tolerance to sdf proteins by pep- 
tide presentation. Science (Wash. DC).  247:1587. 
23. Lombardi,  G., S. Sidhu,  J.R. Batchdor, and R.I. Lechler. 1989. 
Allorecognition of DR1 by T cells from a DR4/DRw13 re- 
sponder mimics self-restricted  recognition of endogenous pep- 
tides. Proc. Natl. A_cad. Sci. USA.  86:4190. 
1668  T Cell Recognition of Self HLA-DR Peptides 